electroCore Announces Proposed Public Offering of Common Stock
29 Junho 2021 - 5:01PM
electroCore, Inc. (the “Company”), NASDAQ: ECOR), a
commercial-stage bioelectronic medicine company, today announced
that it intends to offer and sell shares of its common stock in an
underwritten public offering. All the shares to be sold in the
offering will be offered by the Company. The offering is subject to
market conditions and there can be no assurance as to whether or
when the offering may be completed, or as to the actual size or
terms of the offering. In addition, the Company intends to grant
the underwriters a 45-day option to purchase up to an additional 15
percent of shares of its common stock offered in the public
offering.
Ladenburg Thalmann & Co. Inc. is acting as sole
book-runner for the offering. Paulson Investment Company, LLC is
acting as a co-manager for the offering.
The Company intends to use the net proceeds of the offering for
sales and marketing, working capital, and general corporate
purposes. In addition, it believes that opportunities may exist
from time to time to expand its current business through
acquisitions or in-licenses of, or investments in, complementary
companies, medicines, intellectual property or technologies. While
the Company has no current agreements or commitments for any
specific acquisitions, in-licenses or investments at this time, it
may use a portion of the net proceeds for these purposes.
The securities described above are being offered by the Company
pursuant to an effective shelf registration statement on Form S-3
(File No. 333-232655) previously filed with the Securities and
Exchange Commission (“SEC”) on July 15, 2019, which registration
statement became effective on September 5, 2019. The securities
will be offered by means of a prospectus supplement and
accompanying prospectus relating to the offering that form a part
of the registration statement. A preliminary prospectus supplement
and the accompanying prospectus relating to and describing the
terms of the offering will be filed with the SEC and will be
available on the SEC’s website at http://www.sec.gov. Copies of the
preliminary prospectus supplement and accompanying prospectus
relating to the offering may also be obtained, when available, from
Ladenburg Thalmann & Co. Inc., 640 Fifth Avenue, 4th Floor, New
York, NY 10017, or by email at prospectus@ladenburg.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy any of the securities described
herein, nor shall there be any sale of these securities in any
state or jurisdiction in which such offer, solicitation or sale
would be unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
About electroCoreelectroCore,
Inc. is a commercial stage bioelectronic medicine company dedicated
to improving patient outcomes through its platform non-invasive
vagus nerve stimulation therapy initially focused on the treatment
of multiple conditions in neurology. The company’s current
indications are for the preventative treatment of cluster headache
and migraine and acute treatment of migraine and episodic cluster
headache.
For more information, visit www.electrocore.com.
Forward Looking StatementsThis press release
contains forward-looking statements that involve substantial risks
and uncertainties for purposes of the safe harbor provided by the
Private Securities Litigation Reform Act of 1995. Any statements,
other than statements of historical fact included in this press
release, including those regarding the anticipated use of proceeds
for the proposed offering, satisfaction of the customary closing
conditions of the offering, delays in obtaining required stock
exchange or other regulatory approvals, stock price volatility and
the impact of general business and economic conditions are
forward-looking statements. electroCore may not actually achieve
the plans, carry out the intentions or meet the expectations or
projections disclosed in any forward-looking statements such as the
foregoing and you should not place undue reliance on such
forward-looking statements. Such statements are based on
management’s current expectations and involve risks and
uncertainties, including those discussed under the heading "Risk
Factors" in electroCore’s Annual Report on Form 10-K for the fiscal
year ended December 31, 2020, filed with the SEC on March 11, 2021
and in subsequent filings with, or submissions to, the SEC. Except
as otherwise required by law, electroCore disclaims any intention
or obligation to update or revise any forward-looking statements,
which speak only as of the date they were made, whether as a result
of new information, future events or circumstances or
otherwise.
Investors:
Rich Cockrell
CG Capital
404-736-3838
ecor@cg.capital
or
Media Contact:
Summer Diaz
electroCore
816-401-6333
summer.diaz@electrocore.com
electroCore (NASDAQ:ECOR)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
electroCore (NASDAQ:ECOR)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024